Justin is a partner specialising in venture and growth capital work for early stage and growing technology companies and the investors who support them.
He advises companies, investors and founders on venture and growth capital transactions at all stages from pre-seed through seed, Series A and on to larger institutional investment rounds. He also advises on M&A/exit deals and corporate matters generally.
His practice covers all aspects of the technology sector, but he has a focus on deals in the life sciences sector, and a particular expertise in advising in relation to commercialisation deals involving technologies developed at the UK's leading universities and research institutions.
Helping you succeed in tomorrow's world
The UK is a really exciting place to be involved in science and innovation. I use my experience and knowledge to help the successful commercialisation of the best ideas. This can mean offering guidance and mentoring to founders of new companies or delivering complex funding or exit transactions – all of which is rewarding and always interesting.
Clients praise Justin Starling's ability to get to the issue quickly and always focus on the commercial importance rather than getting bogged down in legal arguments. He is well versed in the representation of investors and investees in the venture capital space, and is particularly active in the technology sector. (Venture Capital UK, Chambers 2019).
Advised Amphista Therapeutics on its $53m Series B funding round led by Forbion and Gilde Healthcare with Novartis Venture Fund, Eli Lilly, BioMotiv and Advent Life Sciences.
UCL Technology Fund/Apollo Healthcare
Advised the UCL Technology Fund on its investment in Apollo Therapeutics as part of a $145 million financing led by Patient Square Capital, with participation from additional investors including Rock Springs Capital and Reimagined Ventures.